^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tobemstomig (RG6139)

    i
    Other names: RG6139, RO7247669, PD1-LAG3 BsAb, RG 6139, RO 7247669, RG-6139, RO-7247669
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    22d
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2025 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    2ms
    Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. (PubMed, Nat Med)
    The NADINA trial evaluating neoadjuvant nivolumab plus ipilimumab and the SWOG-1801 trial evaluating neoadjuvant pembrolizumab have demonstrated superior clinical outcomes with neoadjuvant versus adjuvant checkpoint inhibition...Tobemstomig plus tiragolumab and atezolizumab plus tiragolumab showed a lower pRR versus nivolumab plus ipilimumab (60.0% (12/20) and 45.0% (9/20) versus 77.3% (17/22), respectively)...In conclusion, in the Morpheus-Melanoma study, tobemstomig demonstrated a similar pathological response and improved safety profile versus nivolumab plus ipilimumab in patients with resectable stage III melanoma. ClinicalTrials.gov identifier: NCT05116202 .
    P1/2 data • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    4ms
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2026 --> Oct 2025 | Trial primary completion date: Oct 2026 --> Oct 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    5ms
    Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 expression
    |
    tobemstomig (RG6139)
    7ms
    A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=62, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | N=150 --> 62
    Enrollment closed • Enrollment change
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    9ms
    A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=206, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    10ms
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: May 2025 --> Oct 2026
    Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    10ms
    A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Hoffmann-La Roche | N=160 --> 83
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    11ms
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=93, Active, not recruiting, Hoffmann-La Roche | Phase classification: P2 --> P1/2
    Phase classification
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    11ms
    Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Hoffmann-La Roche | N=320 --> 170
    Enrollment change
    |
    PD-L1 expression
    |
    tobemstomig (RG6139)
    11ms
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=93, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2025 --> May 2024
    Enrollment closed • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)